Search results
Author(s):
Robert J Petrella
Added:
3 years ago
Hypertension is a chronic condition and a leading risk factor for the development of cardiovascular (CV) events, which are a major cause of morbidity and mortality worldwide.1–4 CV events create a significant clinical management and economic burden, and are a major cause of hospitalisation and physician visits.5 The burden associated with CV events may be alleviated by treating hypertension,…
View more
Author(s):
Alessandro Pingitore
,
Giorgio Iervasi
,
Francesca Forini
Added:
3 years ago
Cardioprotection includes all methods and mechanisms that lead to the reduction in infarct size, and is thus involved in the evolution of post-ischaemic heart failure (HF). This is a growing research issue since ischaemic heart disease is the leading cause of morbidity and mortality worldwide. A key challenge for these studies is the unravelling of cardioprotection complexities such as the…
View more
Author(s):
Andrew Carson
Added:
3 years ago
For many years cardiovascular disease has been a major cause of morbidity and mortality across the developed world, and its incidence is also increasing in many developing countries. Indeed, it has recently been shown that even Egyptian mummies, representing the more affluent members of their society several thousand years ago, had established atherosclerosis in multiple blood vessels.1…
View more
Author(s):
Sebastian Schnaubelt
,
Andreas Hammer
,
Lorenz Koller
,
et al
Added:
3 years ago
Cardiovascular disease is a major cause of morbidity and mortality worldwide. While traditional treatment protocols follow physical or pharmaceutical interventions, the mental approach of meditation has been used for centuries to induce beneficial changes to the patients’ cardiovascular risk profile. However, scientific refurbishment of this technique has in the past raised questions of…
View more
Author(s):
Volkmar Falk
Added:
3 years ago
Author(s):
Bernard Man Yung Cheung
,
Y Fei
,
MF Tsoi
Added:
3 years ago
Aim: Lowering systolic blood pressure (SBP) to <120 mmHg has been shown to reduce cardiovascular events and mortality. Whether this should be the target is controversial. We therefore studied the relationship between SBP attained and outcome using network meta-analysis.
Methods: We searched for randomised trials comparing different SBP targets. The mean SBP attained was classified into five…
View more
Author(s):
Javed Butler
Added:
2 years ago
In this short interview, Dr Javed Butler (University of Mississippi Medical Center, Jackson, MS, US) discusses the findings of an analysis from the EMPEROR Preserved trial. In EMPEROR-Preserved, empagliflozin treatment was associated with reduction in the risk of the primary endpoint of CV death or HF hospitalization in patients with HFpEF. In this analysis, presented at AHA 2021, the…
View more
Author(s):
Bernard Man Yung Cheung
,
Y Fei
,
MF Tsoi
Added:
3 years ago
Aim: New antidiabetic drugs are required to be evaluated in cardiovascular outcome trials (CVOTs). Few of these are direct comparisons between new drugs, so we performed a network meta-analysis to compare the new drug classes in terms of cardiovascular outcomes.
Method: We searched for CVOTs involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2)…
View more
Author(s):
Lee Kaplan
,
Fatima Cody Stanford
,
Filip Knop
,
et al
Added:
8 months ago
Radcliffe Medical Education bring together a distinguished panel of globally renowned experts who provide guidance on navigating the ever-changing landscape of obesity and metabolic health management.
Under the chairmanship of Prof Jason Halford(University of Leeds, UK), the panel includingDr Lee Kaplan(Obesity, Metabolism and Nutrition Institute, Massachusetts General Hospital, US),Dr…
View more
Author(s):
Maki Komiyama
,
Koji Hasegawa
Added:
3 years ago
The novel coronavirus disease 2019 (COVID-19) first occurred in December 2019 in Wuhan, Hubei Province, China, and has already evolved into a rapidly expanding pandemic. The WHO has declared COVID-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to be a public health emergency of international concern.1 Until effective therapeutics and vaccines become available…
View more